钠-葡萄糖协同转运蛋白2抑制剂除降糖以外的作用及研究进展  

Progress in the study of Sodium glucose cotransporter-2 inhibitors in addition to hypoglycemic effect

作　　者：毛英 熊莉云 吕敬龙 郭莲 MAO Ying;XIONG Li-yun;LV Jing-long(North Sichuan Medical College,Sichuan Nanchong 637000,China)

机构地区：[1]川北医学院,四川南充637000 [2]重庆大学附属三峡医院内分泌科,重庆404000 [3]重庆大学附属三峡医院血液内科,重庆404000

出　　处：《黑龙江医学》2022年第7期894-896,F0003,共4页Heilongjiang Medical Journal

摘　　要：2型糖尿病(T2DM)是一种发病率及死亡率均较高的慢性疾病,口服药物是其重要治疗方式,但传统降糖药物不能长久稳定的控制血糖,且可引起低血糖、体重增加等不良反应。钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)是一种主要作用于肾脏近曲小管的新型降糖药,可抑制葡萄糖重吸收,促进葡萄糖以尿糖形式排泄发挥治疗作用。近来研究发现,除降糖作用外,SGLT2i还可以改善尿蛋白、血压、体重、肝脂肪变性、氧化应激和炎症等,具有保护心血管、延缓肾脏病变进展及改善非酒精性脂肪性肝病(NAFLD)的作用。本文概述了SGLT2i作用机制、肾脏作用、心血管作用及肝脏保护等方面的研究新进展。Type 2 diabetes mellitus(T2DM)is a chronic disease with high morbidity and mortality.Oral drugs are an important treatment,but traditional hypoglycemic drugs can not control blood sugar for a long time,and can cause adverse reactions such as hypoglycemia and weight gain.Sodium-glucose cotransporter(SGLT2)inhibitor is a new type of hypoglycemic drug which mainly acts on renal proximal convoluted tubules.It can inhibit glucose reabsorption and promote glucose excretion in the form of urine glucose to play a therapeutic role.Recent studies have found that,in addition to hypoglycemic effect,SGLT2 inhibitors can also improve urinary protein,blood pressure,body weight,liver steatosis,oxidative stress and inflammation,protect cardiovascular system,delay the progression of renal disease and improve(NAFLD)in non-alcoholic fatty liver disease.This paper summarizes the new progress in the mechanism of action,kidney effect,cardiovascular effect and liver protection of SGLT2 inhibitors.

关 键 词：钠-葡萄糖协同转运蛋白2抑制剂 肾脏作用 心血管作用 非酒精性脂肪性肝病 

分 类 号：R58[医药卫生—内分泌]